Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
April 2010

Depression during Pregnancy
New guidelines aid clinicians in treating pregnant women with depression.

SSRIs versus an SNRI
A new study failed to find enhanced benefit from duloxetine (Cymbalta) compared with generic selective serotonin reuptake inhibitors in patients with depression.

Zopiclone and Morning-After Impairment
In a small trial of older adults, driving ability and cognitive performance were impaired the morning after subjects took a dose of zopiclone at bedtime.

In Brief
Antipsychotic Polypharmacy Does Not Increase Mortality Risk in Schizophrenia; Tarenflurbil Fails to Slow Cognitive Decline in Alzheimer’s Disease

Second-Generation Antipsychotics Cause Weight Gain and Adverse Metabolic Effects in Young Patients
Second-generation antipsychotics can be life-saving for youth with serious psychiatric illnesses, but they carry the risk for weight gain and possible long-term cardiovascular and metabolic problems.

Second-Generation Antipsychotics Cause Weight Gain and Adverse Metabolic Effects in Young Patients

April 2010

Antipsychotic medications are increasingly being prescribed for children and adolescents in the United States.1 With the exception of clozapine (Clozaril and others), all second-generation agents now are given to children for multiple behavioral indications. But only two have been approved…

To view the rest of this article, please: